Bladder Cancer Awareness

In these videos, Arnold I. Chin, MD, PhD, associate professor of urology at the University of California, Los Angeles, discusses:

• Recent advancements in bladder cancer treatment, including the use of chemotherapy, immunotherapies, antibody-drug conjugates such as enfortumab vedotin (Padcev; Astellas, Seagen), and targeted therapies such as erdafitinib (Balversa, Janssen);
• Upcoming research on the sequence of these treatments among patients with bladder cancer;
• Why it is ‘very critical’ to have a multidisciplinary care team when treating patients;
• Risk factors– including age, race, environmental risk factors and smoking states – and what they mean for bladder cancer screening;
• Molecular subtypes, “biologically-based” treatment options, treatment resistance and other research areas in bladder cancer; and
• The need to continue efforts to educate patients on bladder cancer, particularly the increased risk for the disease with smoking status, which is “a big impact that we can have to change the course of bladder cancer, even preventing bladder cancer [cases] from occurring.”